Work

Lazertinib: A Cardio‐Safer Alternative to Osimertinib for Epidermal Growth Factor Receptor L858R/T790M Double‐Mutant Tyrosine Kinase Resistant Non‐Small Cell Lung Cancer

Year: 2025

Type: article

Source: Drug Development Research

DOI: 10.1002/ddr.70153

Authors: Chandrakant S. Gawli, Narendra R. Nagpure, Bhatu R. Patil, Nobuaki Ochi, Nagio Takigawa, Harun M. Patel

Institution: Kawasaki Medical School

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4414065899

FWCI: 1.823

Cites: 43

Cited by: 3

Related to: 10